Clinical Trial

Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2026 (before its estimated July 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
Proteinuria is an early marker of diabetic kidney disease and predicts progression to chronic kidney disease and cardiovascular complications. ARBs are proven to reduce proteinuria and slow renal damage, even in normotensive diabetic patients. SGLT2 inhibitors have recently shown additional reno-protective effects, including further reduction in proteinuria and slowing of disease progression. Combining ARBs with SGLT2 inhibitors may provide additive or synergistic benefits. However, there is limited data comparing ARBs alone versus the combination in normotensive diabetic patients. This study will provide evidence on the most effective strategy to reduce proteinuria, potentially lowering morbidity and preventing complications in this population
Trial Details
NCT Number NCT07586371
Lead Sponsor Dr Mudassar Saeed Pansota
Conditions Proteinuria, Diabetes (DM)
Enrollment 60 participants
Start Date 2026-04-06
Primary Completion 2026-07-05 (estimated)
Study Completion 2026-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-14